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Abstract
Aims/hypothesis Glucagon-like peptide (GLP)-1-based
therapies have been suggested to improve hepatic steatosis.
We assessed the effects of the GLP-1 receptor agonist
liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor
sitagliptin on hepatic steatosis and fibrosis in patients with
type 2 diabetes.
Methods In this 12 week, parallel, randomised, placebo-
controlled trial, performed at the VU University Medical
Center between July 2013 and August 2015, 52 overweight
patients with type 2 diabetes treated with metformin and/or
sulphonylurea agent ([mean ± SD] age 62.7 ± 6.9 years,
HbA1c 7.3±0.7% or 56±1 mmol/mol) were allocated to once
daily liraglutide 1.8 mg (n=17), sitagliptin 100 mg (n=18) or
matching placebos (n=17) by computer generated numbers.
Both participants and researchers were blinded to group
assignment. Hepatic fat content was measured using proton
magnetic resonance spectroscopy (1H-MRS). Hepatic fibrosis
was estimated using three validated formulae.
Results One patient dropped out in the sitagliptin group
owing to dizziness, but no serious adverse events occurred.
At week 12, no between-group differences in hepatic steatosis
were found. Liraglutide reduced steatosis by 10% (20.9
± 3.4% to 18.8 ± 3.3%), sitagliptin reduced steatosis by
12.1% (23.9±3.0% to 21.0±2.7%) and placebo lessened it
by 9.5% (18.7±2.7% to 16.9±2.7%). Neither drug affected
hepatic fibrosis scores compared with placebo.
Conclusions/interpretation Twelve-week liraglutide or
sitagliptin treatment does not reduce hepatic steatosis or
fibrosis in type 2 diabetes.
Trial registration ClinicalTrials.gov NCT01744236
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most
common chronic liver condition in the developed world,
affecting over 30% of the population [1]. Its prevalence is
particularly high among patients with type 2 diabetes mellitus
(>70%), probably because of insulin resistance as a common
denominator. NAFLD may progress to non-alcoholic
steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma,
and is an independent risk factor for cardiovascular disease [1].
As such, it is associated with increased liver-related and
all-cause mortality.
Lifestyle modifications, including dietary changes and
weight loss, are the mainstay of NAFLD management, yet
most patients with type 2 diabetes do not achieve or maintain
their goals [1]. Moreover, although several pharmacological
substances have been explored with promising results,
including pioglitazone (reductions of up to approximately
50%), vitamin E and obeticholic acid [1], no drug is currently
licensed for NAFLD.With an expected increase in prevalence
of type 2 diabetes, NAFLD and consequent health risks,
the search for effective and safe therapeutic strategies is
ongoing.
Glucagon-like peptide (GLP)-1 receptor agonists and
dipeptidyl peptidase (DPP)-4 inhibitors have been postulated
as treatment options for NAFLD because of their positive
effects on glycaemic control, body weight, insulin resistance,
lipid metabolism and inflammation [2]. Encouraged by
several experimental and open-label uncontrolled clinical
studies [2], the current placebo-controlled randomised trial
assessed the effects of the GLP-1 receptor agonist liraglutide
and the DPP-4 inhibitor sitagliptin on spectroscopy-measured
hepatic steatosis in patients with type 2 diabetes.
Methods
Patients were evaluated in a 12-week, single-centre,
randomised, placebo-controlled, double-blind, double-dummy,
three-armed, parallel-group intervention trial. The study was
approved by the local ethics review board, registered at
ClinicalTrials.gov (NCT01744236) and conducted in
accordance with the Declaration of Helsinki and the
International Conference on Harmonization of Good Clinical
Practice. All participants provided written informed consent
before participation. This study was part of a larger trial
performed between July 2013 and August 2015 at the VU
University Medical Center, Amsterdam, the Netherlands,
whose study objectives and protocol have previously been
published [3]. Here, the effects of GLP-1-based therapies on
the secondary endpoints of hepatic steatosis (measured using
proton-magnetic resonance spectroscopy [1H-MRS]), hepatic
fibrosis (assessed by fibrosis formulae) and hepatic function
(from measurements of serum albumin and bilirubin) are
reported.
Study population Patients with type 2 diabetes were eligible
if they were aged between 35 and 75 years (and women
were postmenopausal), had an HbA1c level of 6.5–9.0%
(48–75 mmol/mol), been treated with a stable dose of
metformin and/or sulfonylurea derivatives for ≥3 months
and had a BMI of 25–40 kg/m2. Relevant exclusion criteria
were the use of GLP-1-based therapies or insulin, a history of
hepatic or pancreatic disease, inability to undergo MRI
scanning and alcohol intake >3 units/day [3].
Intervention After inclusion, a 4-week run-in period and
baseline testing, patients were randomised by the trial
pharmacist using computer-generated numbers (allocation
1:1:1, block size six) to receive the GLP-1 receptor agonist
liraglutide 1.8 mg (Novo Nordisk A/S, Bagsvaerd, Denmark),
the DPP-4 inhibitor sitagliptin 100 mg (Merck, Kenilworth,
NJ, USA) or matching placebos, taken once daily in the
evening.Endpointmeasurementswere repeated after 12weeks
of treatment.
Endpoint measurements Hepatic fat content was measured
using proton 1H-MRS on a 1.5 T whole-body MRI scanner
(Magnetom Avanto; Siemens Medical Solutions, Erlangen,
Germany), with patients in the supine position and the
body-array coil positioned at the upper abdominal region.
Coronal and transverse structural T2-weighted images were
used to localise a volume of interest (VOI). An 8 cm3 VOI
(2×2×2 cm3) was selected at up to three locations in the liver
(right superior, right inferior and left anterior), avoiding major
blood vessels and bile ducts, and with sufficient distance from
the liver edges. Using point-resolved spectroscopy sequences
(echo time 30 ms, retention time 2000 ms, during free
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breathing, no gating), single voxel spectra were recorded.
Eight acquisitions were obtained per VOI, and stored
separately. User-independent spectral quantification was
performed with LCModel (version 6.1; available from
http://s-provencher.com).
Fat content was expressed as the percentage of the area
under the methyl (0.9 ppm) and methylene (1.3 ppm) peaks,
relative to the area under the water (4.65 ppm) peak. For each
VOI, individual acquisitions were reviewed in order to discard
occasional poor-quality spectra (e.g. due to motion artefacts).
Individual spectra were combined to obtain the fat percentage
for each VOI. The mean fat content of the available VOIs was
used. Variation was assessed in 11 patients who underwent an
additional baseline 1H-MRS session within 3 weeks as part of
a different study [3]. The within-VOI variation was 6.7%, the
between-VOI variation 12.2% and the variation in liver fat
(combination of three VOIs; day-to-day variance) 11.7%.
Hepatic fibrosis was estimated at baseline and 12 weeks
using validated formulae: the NAFLD fibrosis score (NFS),
Fibrosis-4 (FIB-4) score and aspartate aminotransferase to
platelet ratio index (APRI) [4]. Fasting blood samples were
drawn for measurement of glucose (gluco quant-hexokinase
method), HbA1c (HPLC), insulin (immunometric method),
(cholestatic) liver enzymes (enzymatic assessment), albumin,
total and conjugated bilirubin (colorimetric measurement),
thrombocyte count (laser light scattering) and liver fatty acid
binding protein (L-FABP; using sandwich ELISA).
Sample size, data management and statistical analysis
Sample size calculations have previously been published [3].
With an expected reduction in the percentage of steatosis of
approximately 50% [5], a total of 13 patients per treatment
arm were needed (parallel-group design, α= 0.05, power
[1−β] 80%). To test treatment effects vs placebo, multivariable
regression analyses were performed on the per-protocol
population, using SPSS 22 (IBM SPSS, Chicago, IL, USA).
Treatment with liraglutide or sitagliptin was added as a dummy
variable. To correct for baseline differences, pretreatment
values were included in the model. Moreover, proportions of
patients with any improvement in steatosis in each treatment
groupwere compared using theχ2 test. Analyses were repeated
in the subgroup with NAFLD (>5.56% steatosis) at baseline. A
two-sided p≤0.05 was considered to be statistically significant.
Results
Of the 52 patients who were randomised, one patient in the
sitagliptin group withdrew from the study because of adverse
effects (dizziness and daytime urinary frequency). Fifty-one
patients completed the 12 week study (17 per treatment arm)
(see electronic supplementary material [ESM] Fig. 1). The
baseline characteristics were similar between the groups
(Table 1). Liraglutide and sitagliptin reduced fasting glucose
(−1.6±0.5 mmol/l and −1.8±0.5 mmol/l, respectively; both
p<0.001) and HbA1c (−1.3±0.2% [−14±2 mmol/mol] and
−0.9 ± 0.2% [−10 ± 2 mmol/mol], respectively; both
p< 0.001), compared with placebo. Liraglutide tended to
reduce the participant’s weight (−1.9±1.0 kg; p=0.06), where-
as sitagliptin was weight-neutral (−0.6±1.0 kg; p=0.56).
Twelve-week treatment with liraglutide or sitagliptin did
not affect hepatic steatosis (−10% and −12.1% from baseline,
respectively), no different from placebo (−9.5%; p=0.98 for
both) (Table 1, Fig. 1). In addition, the proportion of patients
with any reduction in hepatic fat content was similar in the
three groups: liraglutide 60.0%, sitagliptin 62.5%, and
placebo 68.8%.
Neither liraglutide nor sitagliptin affected NFS, FIB-4 or
APRI compared with placebo (all p> 0.05) (Table 1). No
treatment-induced differences occurred in plasma aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
gamma glutamyl transferase (γGT), alkaline phosphatase
(ALP) or L-FABP concentrations (Table 1). Compared with
placebo, liraglutide and sitagliptin reduced plasma albumin
levels (−1.4 ± 0.6 g/l, p= 0.03 and −1.7 ± 0.6 g/l, p=0.01,
respectively), without affecting total or conjugated bilirubin
(p>0.05 for both).
As shown in Fig. 1, baseline hepatic fat content (Fig. 1a)
did not determine treatment effects . Moreover, a subanalysis
of patients with NAFLD at baseline (liraglutide n = 15,
sitagliptin n=16, placebo n=15) did not yield different results
(data not shown).
Discussion
In the current study, we did not observe a beneficial effect of
12 week liraglutide or sitagliptin treatment on hepatic steatosis
or fibrosis. Although high-quality human studies were lacking
when the present study was designed, several randomised
controlled trials have in the meantime been performed and
published. In line with our findings, Tang et al demonstrated
no effect of 12 week treatment with liraglutide on
MRI-measured liver fat [6]. Moreover, 24 week treatment
with sitagliptin did not affect liver fat in patients with
NAFLD when compared with placebo [7]. In contrast, a
48 week double-blind, placebo-controlled trial with liraglutide
demonstrated an improvement in steatosis and a histological
resolution of NASH in patients with and without type 2
diabetes [8]. Also, 26 week treatment with exenatide reduced
hepatic fat by 24% [9]. A 6 month, double-blind,
placebo-controlled, randomised controlled trial reported a
27% reduction in hepatic fat with vildagliptin that was
unrelated to changes in body weight [10]. Finally, an
open-label trial comparing sitagliptin with glimepiride found
no change in intrahepatic fat content after a 12week treatment,
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but reported a 15% decrease after 24 weeks [11]. These
contradictory outcomes may result from differences in
treatment duration, study population and the method used to
assess hepatic fat.
Albeit only as statistical trend, liraglutide decreased body
weight within the expected range [12]. In recent studies with
liraglutide [8, 13], weight loss reached a nadir after 24 weeks,
indicating that further weight loss could have been observed
with a longer duration of the current trial. Since weight loss
per se reduces hepatic steatosis [14], a longer trial might have
yielded different results.
Unexpectedly, we observed a modest decrease in plasma
albumin levels in the liraglutide and sitagliptin groups, for
which we cannot provide an explanation. Inhibition of hepatic
synthetic function seems unlikely, as bilirubin levels remained
unchanged and an increased risk of bleeding due to GLP-1
based therapies has never been reported. In addition, other
potential causes, such as inflammation or renal loss of
albumin, were not observed.
The limitations of the current study were untriggered
magnetic resonance spectroscopy measurements and manual
VOI positioning. To diminish the effect of small variations
before and after intervention, we averaged over three positions
in the liver. Proton-density fat fraction MRI is an alternative
and widely available option [15]. Although the sample size
was small, it is unlikely that a larger trial would have yielded
different results given the minimal between-group differences.
In conclusion, 12 week treatment with liraglutide or
sitagliptin did not improve hepatic steatosis or fibrosis in
overweight patients with type 2 diabetes. Further, longer term
studies are needed to assess the potential of these agents as
treatment strategy for NAFLD.
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None of the effects was
statistically significant (p< 0.05)
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